GlassScriptPhysician profile
Alisa Paulus
NPI 1538581582
$6,136.54
in general payments reported to CMS, 2019-2025
32 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $564 · 2023: $1,675 · 2024: $2,506 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,572.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $790.71 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $746.48 | 2022-2025 | |
| Lilly USA, LLC | $529.50 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $296.19 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.73 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $220.41 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $214.81 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $208.63 | 2022-2025 | |
| Glaxosmithkline, LLC. | $138.42 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.99 | 2022-2025 | Xifaxan |
| Amgen INC. | $134.46 | 2023-2025 | Otezla, Repatha, Repatha |
| Gilead Sciences, INC. | $84.06 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $83.60 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Dexcom, INC. | $83.50 | 2022-2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $72.11 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $67.08 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $59.23 | 2024-2025 | Auvelity |
| Shield Therapeutics INC | $45.01 | 2023-2024 | Accrufer |
| Corcept Therapeutics | $44.36 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $44.21 | 2022 | |
| Sanofi Pasteur INC. | $42.57 | 2023 | |
| Esperion Therapeutics, INC. | $39.30 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $34.09 | 2024 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $32.10 | 2023-2024 | Gvoke Hypopen |
| Pulmonx Corporation | $29.88 | 2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Lucid Diagnostics INC. | $22.88 | 2024 | |
| Eisai INC. | $21.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $18.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.58 | 2023 | |
| Inspire Medical Systems, INC. | $14.49 | 2025 | Inspire |
| Tolmar, INC. | $14.01 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisa Paulus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.